261 Diagnostic utility of molecular and imaging biomarkers 2 Table 64. Estimated pooled test performance of [18F]FDG-PET in indeterminate thyroid nodules minus nodules with known Hürthle cell cytology ni test+ test- test? nH (%) TP FP FN TN malignancy rate (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Kresnik 2003 35 21 14 35 (100%) 9 1 0 14 26% 100 (66-100) 93 (68-100) 10.13 (2.19-46.80) 0.06 (0.00-0.83) Mitchell 2005 24 15 9 24 (100%) 1 13 0 9 4% 100 (3-100) 41 (21-64) 1.28 (0.54-3.05) 0.61 (0.05-7.01) de Geus-Oei 2006 42 19 23 42 (100%) 4 8 0 21 10% 100 (40-100) 72 (53-87) 3.18 (1.68-6.02) 0.14 (0.01-1.95) Kim 2007 36 36 0 36 (100%) 13 19 0 0 36% 100 (75-100) 0 (0-18) 0.99 (0.87-1.12) 1.43 (0.03-67.81) Sebastianes 2007 42 30 12 42 (100%) 11 19 0 12 26% 100 (72-100) 39 (22-58) 1.57 (1.16-2.13) 0.11 (0.01-1.66) Hales 2008 15 11 4 15 (100%) 4 3 1 3 33% 80 (28-99) 50 (12-88) 1.60 (0.64-3.98) 0.40 (0.06-2.75) Traugott 2010 51 24 27 51 (100%) 6 14 2 24 16% 75 (35-97) 63 (46-78) 2.04 (1.14-3.63) 0.40 (0.12-1.35) Deandreis 2012 56 30 26 56 (100%) 6 3 2 16 14% 75 (35-97) 84 (60-97) 4.75 (1.56-14.45) 0.30 (0.09-1.00) Muñoz Pérez 2013 46 29 17 46 (100%) 9 12 1 16 22% 90 (55-100) 57 (37-76) 2.10 (1.31-3.38) 0.17 (0.03-1.15) Piccardo 2016 87 46 41 87 (100%) 17 29 1 40 21% 94 (73-100) 58 (45-70) 2.25 (1.67-3.03) 0.10 (0.01-0.65) POOLED RESULTS 434 261 173 0 434 (100%) 80 121 7 155 20.0% 92.7 (82.8-97.1) 55.7 (35.4-74.3) 2.09 (1.35-3.25) 0.13 (0.06-0.30) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw